Breaking News Instant updates and real-time market news.

DRNA

Dicerna

$3.26

-0.06 (-1.81%)

07:07
07/17/17
07/17
07:07
07/17/17
07:07

Dicerna presents preclinical data on DCR-PHXC

Dicerna Pharmaceuticals presented on July 15, new preclinical data suggesting the potential utility of DCR-PHXC, a GalXC-based investigational therapy, for treating all forms of primary hyperoxaluria. In a series of presentations at the 12th International Workshop on Primary Hyperoxaluria for Professionals, Patients and Families in Tenerife, Spain from July 14-16, 2017, Dicerna scientists presented research from animal models demonstrating how DCR-PHXC inhibits the lactate dehydrogenase A gene, which Dicerna has identified as potentially being an optimal therapeutic target in patients with PH, a group of severe, rare, inherited disorders of the liver that often result in kidney failure. In patients with PH, the liver over-produces oxalate, a metabolite that can accumulate throughout the body and particularly in the kidneys, often resulting in end-stage renal disease and the need for both kidney and liver transplants. DCR-PHXC, the lead investigational product candidate in Dicerna's pipeline of therapies targeting rare diseases of the liver, yields potent, liver-specific LDHA inhibition in animal models of PH, an effect that reduces oxalate to near-normal levels, which may prevent the damage caused to kidneys and other organs by oxalate accumulation. At the 12th International Workshop, Dicerna presented research findings on LDHA inhibition, which was shown in animal models to reduce oxalate to normal or near-normal levels in PH types 1, 2, and ethylene glycol-induced PH. In contrast, research findings showed that inhibiting the enzyme glycolate oxidase -- a common target of investigational therapies for PH, including Dicerna's earlier IV-administered program for PH1 -- does not appear to have the potential to treat PH2 or IPH. In animal models of PH2 and ethylene glycol-induced PH, LDHA knockdown with DCR-PHXC nearly normalized oxalate levels within one-month post-treatment, whereas oxalate levels remained unchanged and elevated in animals receiving GO-targeted therapy. LDHA reduction has a linear correlation with oxalate reduction and offers a minimal metabolic intervention, unlike GO reduction. These benefits of LDHA inhibition may translate into consistent therapeutic activity even in the event of a missed dose. There are numerous case reports of LDHA deficiency naturally occurring in humans, with no reported adverse effects due to deficiency in the liver.

DRNA Dicerna
$3.26

-0.06 (-1.81%)

05/23/17
HCWC
05/23/17
INITIATION
Target $5
HCWC
Buy
Dicerna assumed with a Buy at H.C. Wainwright
H.C. Wainwright analyst Ed Arce assumed coverage of Dicerna Pharmaceuticals with a Buy rating and $5 price target.
01/31/17
LEER
01/31/17
INITIATION
Target $4
LEER
Market Perform
Dicerna assumed with a Market Perform at Leerink
Leerink analyst Paul Matteis assumed coverage of Dicerna with a Market Perform rating and $4 price target. While the analyst believes the company's pipeline has long-term clinical potential, nearer term he is somewhat concerned by its limited cash runway and lack of news flow.
12/12/16
HCWC
12/12/16
INITIATION
Target $7
HCWC
Buy
Dicerna initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Shaunak Deepak started Dicerna Pharmaceuticals with a Buy rating and $7 price target.
11/08/16
LEER
11/08/16
NO CHANGE
Target $8
LEER
Outperform
Dicerna price target lowered to $8 from $18 at Leerink
Following Q3 results and pipeline updates, Leerink analyst Michael Schmidt lowered his price target for Dicerna to $8 from $18 to reflect discontinuation of the DCR-MYC program and a lower probability-of-success of DCR-PHXC to account for additional clinical development risk on novel RNAi platforms. The analyst reiterates an Outperform rating on the shares.

TODAY'S FREE FLY STORIES

AAPL

Apple

$153.46

0.72 (0.47%)

12:34
07/27/17
07/27
12:34
07/27/17
12:34
Periodicals
Apple confirms discontinuation of iPod nano, shuffle, The Verge reports »

Apple is discontinuing…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Aug

HOG

Harley-Davidson

$49.96

1.32 (2.71%)

12:30
07/27/17
07/27
12:30
07/27/17
12:30
Options
Heavy call activity in Harley Davidson as shares rally »

Heavy call activity in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

12:30
07/27/17
07/27
12:30
07/27/17
12:30
General news
Atlanta Fed's final Q2 GDPNow estimate was boosted to 2.8% »

Atlanta Fed's final…

VBIV

VBI Vaccines

$4.61

-0.03 (-0.65%)

12:25
07/27/17
07/27
12:25
07/27/17
12:25
Conference/Events
VBI Vaccines to host conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jul

  • 26

    Sep

DAL

Delta Air Lines

$50.74

-0.395 (-0.77%)

, AFLYY

Air France-KLM

$14.14

0.18 (1.29%)

12:22
07/27/17
07/27
12:22
07/27/17
12:22
Hot Stocks
Delta Air Lines to acquire 10% equity stake in Air France-KLM for EUR375M »

Delta Air Lines (DAL)…

DAL

Delta Air Lines

$50.74

-0.395 (-0.77%)

AFLYY

Air France-KLM

$14.14

0.18 (1.29%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GG

Goldcorp

$12.88

-0.91 (-6.60%)

12:20
07/27/17
07/27
12:20
07/27/17
12:20
Options
Repeat activity in GoldCorp after earnings »

Repeat activity in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jul

12:20
07/27/17
07/27
12:20
07/27/17
12:20
General news
Treasury Option Action: heavy put activity »

Treasury Option Action:…

$NSD

NASDAQ Market Internals

12:17
07/27/17
07/27
12:17
07/27/17
12:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

12:16
07/27/17
07/27
12:16
07/27/17
12:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

W

Wayfair

$78.91

-0.4533 (-0.57%)

12:15
07/27/17
07/27
12:15
07/27/17
12:15
Options
Wayfair put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Aug

TDOC

Teladoc

$31.78

-2.575 (-7.50%)

, AMZN

Amazon.com

$1,052.80

12.93 (1.24%)

12:11
07/27/17
07/27
12:11
07/27/17
12:11
Recommendations
Teladoc, Amazon.com analyst commentary  »

Teladoc selloff on Amazon…

TDOC

Teladoc

$31.78

-2.575 (-7.50%)

AMZN

Amazon.com

$1,052.80

12.93 (1.24%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jul

  • 02

    Aug

  • 16

    Aug

  • 18

    Aug

SBUX

Starbucks

$57.94

-0.61 (-1.04%)

12:11
07/27/17
07/27
12:11
07/27/17
12:11
Technical Analysis
Technical Earnings Preview: Starbucks in consolidation phase before news »

The stock has been…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jul

  • 23

    Aug

AAPL

Apple

$153.46

0.72 (0.47%)

12:06
07/27/17
07/27
12:06
07/27/17
12:06
Periodicals
Breaking Periodicals news story on Apple »

Apple to discontinue iPod…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Aug

NTES

NetEase

$312.15

3.26 (1.06%)

12:05
07/27/17
07/27
12:05
07/27/17
12:05
Options
NetEase call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Aug

WABC

Westamerica

$54.57

-1.82 (-3.23%)

12:04
07/27/17
07/27
12:04
07/27/17
12:04
Hot Stocks
Westamerica announces announces stock repurchase plan »

Westamerica…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

12:00
07/27/17
07/27
12:00
07/27/17
12:00
General news
Treasury's $20 B 14-day cash management bill saw pretty good demand »

Treasury's $20 B…

INTC

Intel

$34.75

0.08 (0.23%)

12:00
07/27/17
07/27
12:00
07/27/17
12:00
Periodicals
Intel sells four offices buildings, development center in Alameda, SVBJ says »

Intel has sold four…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jul

  • 10

    Aug

  • 15

    Aug

  • 28

    Aug

HOG

Harley-Davidson

$49.03

0.39 (0.80%)

, TSLA

Tesla

$343.85

4.25 (1.25%)

11:58
07/27/17
07/27
11:58
07/27/17
11:58
Hot Stocks
Harley-Davidson jumps amid chatter of Tesla partnership »

The move higher in shares…

HOG

Harley-Davidson

$49.03

0.39 (0.80%)

TSLA

Tesla

$343.85

4.25 (1.25%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Aug

  • 08

    Aug

  • 02

    Oct

RYAM

Rayonier Advanced Materials

$15.72

-0.11 (-0.69%)

11:56
07/27/17
07/27
11:56
07/27/17
11:56
Hot Stocks
Tembec shareholders approve deal with Rayonier Advanced Materials »

Rayonier Advanced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Aug

  • 07

    Aug

TKC

Turkcell

$9.29

0.29 (3.22%)

11:55
07/27/17
07/27
11:55
07/27/17
11:55
Hot Stocks
Breaking Hot Stocks news story on Turkcell 

Turkcell trading resumes

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FOSL

Fossil

$10.83

-0.19 (-1.72%)

11:55
07/27/17
07/27
11:55
07/27/17
11:55
Hot Stocks
Breaking Hot Stocks news story on Fossil »

Classic Fund Management…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CSX

CSX

$52.06

0.5 (0.97%)

11:55
07/27/17
07/27
11:55
07/27/17
11:55
Options
CSX put volume heavy and directionally bearish »

Bearish flow noted in CSX…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

EXPE

Expedia

$156.94

2.37 (1.53%)

11:54
07/27/17
07/27
11:54
07/27/17
11:54
Periodicals
Expedia investing $350M in online travel portal Traveloka, The Information says »

Expedia is said to be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jul

NVDA

Nvidia

$167.26

1.91 (1.16%)

, TSLA

Tesla

$343.85

4.25 (1.25%)

11:54
07/27/17
07/27
11:54
07/27/17
11:54
Periodicals
House panel supports speeding self-driving car development, Reuters says »

A House panel voted 54-0…

NVDA

Nvidia

$167.26

1.91 (1.16%)

TSLA

Tesla

$343.85

4.25 (1.25%)

GOOG

Alphabet

$947.80

-2.9 (-0.31%)

GOOGL

Alphabet Class A

$965.31

-3.72 (-0.38%)

INTC

Intel

$34.75

0.08 (0.23%)

AAPL

Apple

$153.46

0.72 (0.47%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jul

  • 01

    Aug

  • 02

    Aug

  • 08

    Aug

  • 10

    Aug

  • 15

    Aug

  • 16

    Aug

  • 18

    Aug

  • 28

    Aug

  • 29

    Aug

  • 02

    Oct

CA

CA Technologies

$34.65

-0.38 (-1.08%)

11:53
07/27/17
07/27
11:53
07/27/17
11:53
Periodicals
CA Technologies, BMC Software merger talks end, WSJ reports »

Merger talks between CA…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Aug

  • 09

    Aug

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.